The Federal Agency for Medicines and Health Products (FAMHP) has received 23,560 notifications of adverse reactions after the administration of a vaccine against Covid-19 since the start of the vaccination campaign, according to its last balance sheet. The majority (62%) are considered non-serious.
Some 62% of these side effects are considered “not serious“while 31% resulted in an inability to work or leave home. Hospitalizations represent 3% of notifications while”significant medical events“total 2% of them.
Fever and muscle aches are among other “common” reactions.
The FAMHP recorded 7,931 reports via the European pharmacovigilance database EudraVigilance. They mainly concern fever, muscle pain, malaise and reactions at the injection site. “These reactions are normal and indicate activation of the immune system. They usually go away after a few days“, assures the Agency.
The vast majority of the 5,354 reports considered serious are “due to temporary incapacity for work or the inability to leave home due to fever, muscle pain, malaise and injection site reactions“, states the AFMPS.
Deaths represent less than 1% of reported adverse reactions, as do cases in which the person vaccinated has a life-threatening prognosis. If 191 reports concern deaths, the federal agency judges that only four of them are “probably related to the vaccine“.
This is a case of capillary hyperpermeability syndrome and immune thrombocytopenia, probably related to the injection of Vaxzevria (AstraZeneca). The other two deaths resulted from a syndrome combining thrombosis and thrombocytopenia, one after vaccination with Janssen and the other with AstraZeneca.
Effects that mostly occur after the injection of the second dose
For messenger RNA sera (Pfizer and Moderna), the effects generally appear after the second injection while the vaccine developed by AstraZeneca seems to have more impact after the first dose.
Anyone who experiences an adverse effect after receiving a serum against the coronavirus is invited to notify it via an online form available on the FAMHP website.